Li-Fraumeni syndrome (LFS) is one of the most penetrant forms of familial cancer susceptibility syndromes, characterized by an early age of tumor onset and a wide spectrum of malignant tumors. Patients with TP53 mutations are predisposed to develop sarcomas, early-onset breast cancer, brain tumors, leukemia, and adrenocortical carcinomas.1,2 The lifetime risk of cancer in these patients is extraordinarily high with 50% of patients having a diagnosis of cancer by the age of 30 and 90% by the age of 50.3 Identifying LFS in patients with cancer is clinically imperative because these patients have an increased sensitivity to ionizing radiation and are more likely to develop radiation-induced secondary malignancies.4–7 This case report describes a young woman whose initial presentation of LFS was early-onset breast cancer and whose subsequent treatment with breast conservation likely resulted in the rapid development of a secondary malignancy arising in her radiation field.
Olivier M, Goldgar DE, Sodha N et al.. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. Cancer Res 2003;63:6643–6650.
Gonzalez KD, Noltner KA, Buzin CH et al.. Beyond Li Fraumeni syndrome: clinical characteristics of families with p53 germline mutations. J Clin Oncol 2009;27:1250–1256.
Lustbader ED, Williams WR, Bondy ML et al.. Segregation analysis of cancer in families of childhood soft tissue sarcoma patients. Am J Hum Genet 1992;51:344–356.
Hisada M, Garber JE, Fung CY et al.. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606–611.
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumours in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238–242.
Cohen RJ, Curtis RE, Inskip PD, Fraumeni JF Jr. The risk of developing second cancers among survivors of childhood soft tissue sarcoma. Cancer 2005;103:2391–2396.
Kony SJ, de Vathaire F, Chrompret A et al.. Radiation and genetic factors in the risk of second malignant neoplasm’s after a first cancer in childhood. Lancet 1997;350:91–95.
Heymann S, Delaloge S, Rahal A et al.. Radio-induced malignancies after breast cancer post operative radiotherapy in patients with Li-Fraumeni syndrome. Radiat Oncol 2010;5:104–109.
Tinat J, Bougeard G, Baert-Desurmont S et al.. 2009 version of the Chrompret criteria for Li-Fraumeni syndrome. J Clin Oncol 2009;27:108–109.
Greenburg CC, Lipsitz SR, Hughs ME et al.. Institutional variation in the surgical treatment of breast cancer: a study of the NCCN. Ann Surg 2011;254:339–345.
Limacher JM, Frebourg T, Natarajan-Ame S, Bergerat JP. Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome. Int J Cancer 2001;96:238–242.
Rubino C, de Vathaire F, Shamsaldin A et al.. Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 2003;895:840–846.
Kleinerman RA. Radiation-sensitivie gentetically susceptible pediatric sub-populations. Pediatr Radiol 2009;39(Suppl 1):S27–31.
Schneider K, Garber J. Li-Fraumeni syndrome. In: Pagon RA, Bird TD, Dolan CR et al., eds. Gene Reviews. Seattle, WA: University of Washington; 1999.
Daly MB, Axilbund JE, Buys S et al.. NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 1, 2012. Available at NCCN.org. Accessed June 18, 2012.
Malkin D, Smyth K, Shuman C et al.. Establishment of a dedicated cancer genetics program in a tertiary pediatric center [abstract]. Am J Hum Genet 1999;65:Abstract 386.
Masciari S, Dillon D, Dick MG et al.. Breast cancer phenotype in women with TP53 germ-line mutations: an LFS consortium effort [abstract]. J Clin Oncol 2011;29(Suppl):Abstract 1519.
Wilson JR, Bateman AC, Hansons H et al.. A novel Her2 positive breast cancer phenotype arising from germline TP53 mutations. J Med Genet 2010;47:771–774.
Melhem-Bertrandt A, Bojadzieva J, Ready KJ et al.. Early onset Her2-positive breast cancer is associated with germline TP53 mutations. Cancer 2012;118:908–913.